SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-053958
Filing Date
2024-05-07
Accepted
2024-05-07 08:00:42
Documents
78
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fusn-20240331.htm   iXBRL 10-Q 1813126
2 EX-31.1 fusn-ex31_1.htm EX-31.1 15038
3 EX-31.2 fusn-ex31_2.htm EX-31.2 15035
4 EX-32.1 fusn-ex32_1.htm EX-32.1 8103
5 EX-32.2 fusn-ex32_2.htm EX-32.2 8841
  Complete submission text file 0000950170-24-053958.txt   9346867

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fusn-20240331.xsd EX-101.SCH 1455255
82 EXTRACTED XBRL INSTANCE DOCUMENT fusn-20240331_htm.xml XML 1729173
Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Filer) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39344 | Film No.: 24919685
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)